Page 3 - Janssen Cilag Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeTamara werner kiechleAl awawdehJanssen cilag gmbCompanies of johnsonJanssen pharmaceutical companies of johnsonJanssen research developmentNone of the janssen pharmaceutical companiesAmerican college of cardiologyJanssen pharmaceutical companiesEuropean medicines agencyWorld health organization groupExchange commissionEuropean society of cardiology respiratoryMarketing authorisation application

Janssen s Erdafitinib significantly extends survival of urothelial cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced its drug Erdafitinib extends survival in bladder cancer.

France generalInstitut gustave roussyYohann loriotJanssen cilag gmbMartin vogelEastern cooperative oncology groupUniversity of parisJanssen cilag gmbhClinical developmentPis active pharmaceutical ingredientsPhase iii ivBladder cancerClinical trialClinical researchPharmaceutical industry

Janssen reveals data from erdafitinib study

Erdafitinib boosted survival in patients with certain conditions including metastatic urothelial carcinoma - News - PharmaTimes

France generalJanssen cilag gmbYohann loriotMartin vogelUniversity of parisJanssen pharmaceutical companies of johnsonJanssen pharmaceutical companiesJanssen cilag gmbh

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Janssen shares positive phase 3 results for erdafitinib in bladder cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesJanssen cilag gmbMartin vogelJanssen pharmaceutical companies of johnsonAmerican society of clinical oncologyDrug administrationJanssen pharmaceutical companiesJanssen cilag gmbhAmerican societyClinical oncology

New Long-Term Data from the CHRYSALIS Study Show Median

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive.

United statesRegion flamandeNoord hollandSouth koreaJanssen cilag gmbMartin vogelHoon leeKiran patelNational cancer instituteJanssen pharmaceutical companiesAmerican society of clinical oncologySamsung medical centerEuropean commissionExchange commissionYuhan corporationCompanies of johnson